Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young lister hooded rats

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 402-411

  Goh, Catherine W ^a   Aw, Chiu Cheong ^a   Lee, Jasinda H ^b   Chen, Christopher P ^b   Browne, Edward R ^a  

^a Neural Pathway Discovery Performance Unit   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; DONEPEZIL; GALANTAMINE; MUSCARINIC RECEPTOR; TACRINE;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; ENZYME ACTIVITY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

AGING; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; HALF-LIFE; HYPOTHERMIA; INDANS; MALE; METABOLIC CLEARANCE RATE; PIPERIDINES; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS; RECEPTOR, MUSCARINIC M2; SALIVATION; TACRINE; TEARS; TREMOR;

RATTUS;

EID: 79951876435     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035964     Document Type: Article

References (36)

1. Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, and Schüttler J (1999) The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65:630-639. (Pubitemid 29294026)
2. Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, and Leenders KL (2009) Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 30: 1818-1824.
3. Baylis C and Corman B (1998) The aging kidney: insights from experimental studies. J Am Soc Nephrol 9:699-709. (Pubitemid 28186060)
4. Beaufrère B and Morio B (2000) Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 54:S48-S53. (Pubitemid 30447300)
5. Brown EA, Griffiths R, Harvey CA, and Owen DA (1986) Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. Br J Pharmacol 87:569-578. (Pubitemid 17178775)
6. Bymaster FP, McKinzie DL, Felder CC, and Wess J (2003) Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437-442. (Pubitemid 36314830)
7. Cusack BJ (2004) Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2:274-302.
8. Dronfield S, Egan K, Marsden CA, and Green AR (2000) Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 14:275-279.
9. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
10. Farlow MR (2003) Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42:1383-1392.
11. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, and Sachak S (2005) Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033:186-193. (Pubitemid 40193413)
12. Goldstein RS, Tarloff JB, and Hook JB (1988) Age-related nephropathy in laboratory rats. FASEB J 2:2241-2251.
13. Hilmer SN (2008) ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol 4:1321-1331.
14. Hovinga S, Stijnen AM, Langemeijer MW, Mandema JW, van Bezooijen CF, and Danhof M (1992) Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. Br J Pharmacol 107:171-177.
15. Hubbard RE, O'Mahony MS, Calver BL, and Woodhouse KW (2008) Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol 64:895-900.
16. Jann MW, Shirley KL, and Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719-739. (Pubitemid 34948194)
17. Jourdan D, Pickering G, Marchand F, Gaulier JM, Alliot J, and Eschalier A (2002) Impact of ageing on the antinociceptive effect of reference analgesics in the Lou/c rat. Br J Pharmacol 137:813-820. (Pubitemid 35404181)
18. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76.
19. Kosasa T, Kuriya Y, Matsui K, and Yamanishi Y (1999) Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur J Pharmacol 386:7-13. (Pubitemid 30009617)
20. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, and Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389. (Pubitemid 46606420)
21. Lotrich FE and Pollock BG (2005) Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45:1106-1122. (Pubitemid 41361911)
22. Mangoni AA and Jackson SH (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6-14.
23. McLean AJ and Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163-184. (Pubitemid 38720828)
24. Ogura H, Kosasa T, Kuriya Y, and Yamanishi Y (2000) Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22:609-613. (Pubitemid 32171225)
25. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, and Tanaka T (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086-1091. (Pubitemid 24002899)
26. Padilla S, Lassiter T, and Hunter D (1999) Biochemical measurement of cholinesterase activity, in Neurodegeneration Methods and Protocols (Harry J and Tilson HA eds) pp 237-246, Humana Press, Totowa, NJ.
27. Pedigo NW Jr, Minor LD, and Krumrei TN (1984) Cholinergic drug effects and brain muscarinic receptor binding in aged rats. Neurobiol Aging 5:227-233. (Pubitemid 15221609)
28. Piotrovsky V, Van Peer A, Van Osselaer N, Armstrong M, and Aerssens J (2003) Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol 43:514-523. (Pubitemid 36506152)
29. Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87-96.
30. Shi S, Mörike K, and Klotz U (2008) The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64:183-199.
31. Siu LL (2007) Clinical trials in the elderly - a concept comes of age. N Engl J Med 356:1575-1576.
32. Sund-Levander M and Grodzinsky E (2009) Time for a change to assess and evaluate body temperature in clinical practice. Int J Nurs Pract 15:241-249.
33. 11C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540-548.
34. Turnheim K (2004) Drug therapy in the elderly. Exp Gerontol 39:1731-1738.
35. Villesen HH, Banning AM, Petersen RH, Weinelt S, Poulsen JB, Hansen SH, and Christrup LL (2007) Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. Ther Clin Risk Manag 3:961-967. (Pubitemid 350162094)
36. Weindruch R and Masoro EJ (1991) Concerns about rodent models for research. J Gerontol Biol Sci 46:B87-B88.